HELSINKI, April 29, 2026
HELSINKI, April 29, 2026 /PRNewswire/ -- Bioretec Ltd Company release 29 April 2026 at 16:40 p.m. EEST
Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Sp-Rahastoyhtiö)
Bioretec Ltd ("Bioretec" or the "Company") has received on 29 April 2026 the following notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Sp-Rahastoyhtiö Oy. According to the notification, the holding of Säästöpankki Pienyhtiöt, an investment fund of Sp-Rahastoyhtiö, in Bioretec's shares and votes has exceeded 5 per cent on 29 April 2026.
The total number of shares and votes in Bioretec is 1,341,785,963.
Bioretec has one series of shares in which each share carries one vote.
The total holding of the notifier in Bioretec's shares and votes according to the notification:
| | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % | Total number of shares and voting rights of issuer |
| Resulting situation on the date on which threshold was crossed or reached | 8.01 % | - | 8.01 % | 1,341,785,963 |
| Position of previous notification (if applicable) | - | - | - | |
A: Shares and voting rights
| | Number of shares and voting rights | % of shares and voting rights | ||
| Class / type of shares | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) |
| FI4000480454 | 107,531,243 | - | 8.01 % | - |
| SUBTOTAL A | 107,531,243 | - | 8.01 % | - |
Contacts
Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736
Tuukka Paavola, CFO, +358 50 386 0013
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
This information was brought to you by Cision http://news.cision.com
View original content:https://www.prnewswire.com/news-releases/bioretec-ltd-notification-pursuant-to-chapter-9-section-10-of-the-finnish-securities-markets-act-sp-rahastoyhtio-302757363.html
SOURCE Bioretec
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
